OncoMatch/Clinical Trials/NCT05362773
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Is NCT05362773 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies MGD024 for leukemia, acute myeloid.
Treatment: MGD024 — CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to determine the safety, tolerability, pharmacokinetics (affect of the body on the drug), pharmacodynamic (affect of the drug on the body), immunogenicity (development of antibodies against the drug), and preliminary anti-cancer effect of MGD024. Participants will receive treatment with MGD024 in consecutive 28-day cycles for a study treatment period of up to 12 cycles (approximately 1 year) or until treatment or study discontinuation criteria are met. Response assessments will be performed after Cycle 1 and then after every even numbered cycle starting with Cycle 2 until progression or study treatment discontinuation. Participants will be checked for side effects throughout the study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Biomarker criteria
Required: IL3RA overexpression (at least 20% of malignant cells with CD123 expression)
Evidence of at least 20% of malignant cells with CD123 expression
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any prior anti-cancer therapy — relapsed or refractory
Relapsed after or refractory to at least one prior line of therapy and with no available potentially curative treatment option
Cannot have received: anti-CD123-directed agent
Exception: patients with BPDCN, who are allowed to have received prior tagraxofusp
Prior treatment with an anti-CD123-directed agent (except patients with BPDCN, who are allowed to have received prior tagraxofusp)
Lab requirements
Blood counts
acceptable laboratory values
Kidney function
acceptable laboratory values
Liver function
acceptable laboratory values
Cardiac function
acceptable heart function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Colorado Blood Cancer Network · Denver, Colorado
- University of Maryland, Greenbaum Comprehensive Cancer Center · Baltimore, Maryland
- Dana Farber Cancer Institute · Boston, Massachusetts
- START - Midwest · Grand Rapids, Michigan
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify